Literature DB >> 15556808

Enzyme-replacement therapy for metabolic storage disorders.

Roscoe O Brady1, Raphael Schiffmann.   

Abstract

BACKGROUND: After many years of intensive investigation, enzyme-replacement therapy (ERT) has become standard treatment for patients with type 1 (non-neuronopathic) Gaucher's disease. ERT has greatly changed the clinical course of this disorder by reducing hepatosplenomegaly, by improving anaemia and thrombocytopenia, and by ameliorating skeletal damage. This example has prompted the investigation of ERT for several other metabolic disorders. The results of several of these trials have recently been published. RECENT DEVELOPMENTS: In addition to Gaucher's disease, the effects of ERT in four other major metabolic storage disorders have been reported. Among these rare orphan diseases are Fabry's disease, in which the heart, kidney, gastrointestinal tract, and peripheral nerves are damaged; Pompe's disease, in which the heart, skeletal muscles, and brain are involved; Hurler's disease and Maroteaux-Lamy syndrome in which the eyes, liver, joints, and skeleton are usually affected. Responses to ERT in these four disorders have generally been encouraging although the degree and extent of benefit vary considerably. WHERE NEXT: There are several critical features of ERT that require attention and amelioration. Among these are the development of severity-score indices that can be used to explicitly quantify the benefit of ERT. The benefit of this treatment has been slight in Fabry's disease and is yet to be fully shown in the other three disorders. Secondly, novel technologies need to be developed to deliver therapeutic enzymes effectively to tissues such as the cardiac muscle and kidney in Fabry's disease, skeletal muscle in patients with Pompe's disease, and to joint tissues and structures in patients with Hurler's disease and Maroteaux-Lamy syndrome. Finally, an all-encompassing concern is to devise methods to ameliorate the damage to the central and peripheral nervous systems that occurs in specific phenotypes of these disorders. In this review we descibe emerging strategies that seem to be useful in these critical regards.

Entities:  

Mesh:

Year:  2004        PMID: 15556808     DOI: 10.1016/S1474-4422(04)00938-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  21 in total

1.  Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency.

Authors:  Matan Rapoport; Lina Salman; Ofra Sabag; Mulchand S Patel; Haya Lorberboum-Galski
Journal:  J Mol Med (Berl)       Date:  2010-11-16       Impact factor: 4.599

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 3.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

Review 4.  Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Cardiol       Date:  2007-08       Impact factor: 2.882

5.  Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.

Authors:  Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Drug Metab Dispos       Date:  2012-07-20       Impact factor: 3.922

6.  Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.

Authors:  F Maccari; N C Sorrentino; V Mantovani; F Galeotti; A Fraldi; N Volpi
Journal:  Metab Brain Dis       Date:  2016-09-01       Impact factor: 3.584

7.  AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.

Authors:  Ruben J Boado; Eric K-W Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  J Biotechnol       Date:  2009-09-06       Impact factor: 3.307

8.  Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.

Authors:  Ulrich Matzner; Renate Lüllmann-Rauch; Stijn Stroobants; Claes Andersson; Cecilia Weigelt; Carl Eistrup; Jens Fogh; Rudi D'Hooge; Volkmar Gieselmann
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

9.  Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families.

Authors:  R Freedman; M Sahhar; L Curnow; J Lee; H Peters
Journal:  J Genet Couns       Date:  2013-03-28       Impact factor: 2.537

10.  Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.

Authors:  Dana Marcus; Michal Lichtenstein; Ann Saada; Haya Lorberboum-Galski
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.